Novel 6p rearrangements and recurrent translocation breakpoints in retinoblastoma cell lines identified by spectral karyotyping and mBAND analyses
Jana Paděrová(Ontario Institute for Cancer Research), Jeremy A. Squire(Universidade de São Paulo), Brenda L. Gallie(University of Toronto), M Orlic-Milacic(Ontario Institute for Cancer Research), Maisa Yoshimoto(University of Alberta), Gilda da Cunha Santos(University Health Network)
Cited by 23
Related Papers
Characterisation of retinoblastomas without RB1 mutations: genomic, gene expression, and clinical studies
|The Lancet Oncology|2013|419
FISH analysis of 107 prostate cancers shows that PTEN genomic deletion is associated with poor clinical outcome
|British Journal of Cancer|2007|294
Absence of TMPRSS2:ERG fusions and PTEN losses in prostate cancer is associated with a favorable outcome
|Modern Pathology|2008|278
First-Line Erlotinib Followed by Second-Line Cisplatin-Gemcitabine Chemotherapy in Advanced Non–Small-Cell Lung Cancer: The TORCH Randomized Trial
|Journal of Clinical Oncology|2012|234
<i>PTEN</i> genomic deletion is associated with p‐Akt and AR signalling in poorer outcome, hormone refractory prostate cancer
|The Journal of Pathology|2009|210